BioCentury | Jun 17, 2020
Deals

With Ideaya deal, GSK bulks up synthetic lethality side of oncology business

A deal with Ideaya gives GSK a path to growing its synthetic lethality pipeline, a corner of the pharma’s cancer rebuild still primarily centered around PARP inhibitor Zejula. On Tuesday, GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) and...
BioCentury | May 28, 2020
Deals

In its first broad deal, Repare leads BMS deeper into synthetic lethality

A discovery collaboration between Repare and BMS is the former’s first time deploying its platform outside its own pipeline, and the latter’s biggest move yet in synthetic lethality. Repare Therapeutics Inc. announced Tuesday it will...
BioCentury | Sep 4, 2019
Finance

Repare readies for clinic with Cowen-led $82M B round

To bring Repare’s pipeline to the clinic and expand the use of its CRISPR-based screening platform, Cowen Healthcare Investments led the synthetic lethality company’s untranched $82.5 million series B round. Cowen’s Kevin Raidy said that...
BioCentury | Jan 11, 2019
Emerging Company Profile

Artios: Probing DNA Damage

With programs in-licensed from Cancer Research UK and Masaryk University, Artios Pharma Ltd. thinks it has next-generation DNA damage response programs that could improve upon PARP inhibitors -- and the funds to take them to...
BC Week In Review | Aug 10, 2018
Financial News

Artios raises £65M series B

Artios Pharma Ltd. (Cambridge, U.K.) raised £65 million ($84.3 million) in an oversubscribed, tranched series B round led by new investors Andera Partners and LSP. Fellow new investors Pfizer Ventures and Novartis Venture Fund also...
BC Extra | Aug 10, 2018
Financial News

Artios raises £65M series B

Artios Pharma Ltd. (Cambridge, U.K.) raised £65 million ($84.3 million) in an oversubscribed, tranched series B round led by new investors Andera Partners and LSP. Fellow new investors Pfizer Ventures and Novartis Venture Fund also...
BC Innovations | May 1, 2018
Translation in Brief

Rewriting cancer’s origin story

A collection of 29 papers published across a suite of Cell journals in April by The Cancer Genome Atlas (TCGA) consortium completed the Pan-Cancer Atlas -- a comprehensive analysis of molecular signatures across cancer types....
BC Innovations | Apr 13, 2018
Targets & Mechanisms

Meeting the burden

A major theme at this year’s AACR is the abundance of preclinical discovery driven by molecular signatures in patient samples, suggesting the research community is heeding the call for studies better grounded in human data,...
BioCentury | Jun 23, 2017
Finance

Synthetic vitality

Versant Ventures and MPM Capital backed Repare Therapeutics Inc. with 2017’s largest series A round to get the synthetic lethality play to clinical proof of concept and possibly an exit. Repare emerged from stealth mode...
BC Week In Review | Jun 23, 2017
Financial News

Repare launches with $68M series A

On June 22, cancer company Repare Therapeutics Inc. (Montreal, Quebec) launched with a $68 million series A round. Versant Ventures , which founded the company, co-led the round with MPM Capital. Also participating were Fonds de...
Items per page:
1 - 10 of 21